[29]
Mane PB, Antre RV, Oswal RJ. Antidiabetic drugs: An overview. Int J Pharm Chem Sci 2012; 1(1): 301-6.
[32]
Ganesan K, Sultan S. Oral hypoglycemic medications Treasure Island. Stat Pearls Publishing 2018.
[34]
Alhadramy MS. Diabetes and oral therapies: a review of oral therapies for diabetes mellitus. J Taibah Univ Med Sci 2016; 11(4): 317-29.
[38]
Kabel AM, Altowirqi R, Thobiti HA, Althumali A, Alharthi E. Pharmacological therapy of type 2 diabetes mellitus: new perspectives. EC Pharmacol Toxicol 2017; 4(1): 12-9.
[97]
Patidar D, Narayan S, Malviya R, Yaduwanshi PS. Study and design of benzamide and pyridinecarboxamide derivatives as a glucokinase activator. World J Pharm Res 2018; 7(7): 980-91.
[111]
Jain N, Pathak A, Mundada A. 3D QSAR study of novel potent benzamide derivatives as glucokinase activator for antidiabetic activity. J Pharm Res 2012; 5(8): 4045-57.
[128]
Grewal AS, Sharma K, Singh S, Singh V, Pandita D, Lather V. Design, synthesis and antidiabetic activity of novel sulfamoyl benzamide derivatives as glucokinase activators. J Pharm Technol Res Manag 2018; 6(2): 113-22.
[167]
Angadi KK, Gundampati RK, Jagannadham MV, Kandru A. Molecular docking studies of guggultetrol from Nymphaea pubescens with target glucokinase (GK) related to type-II diabetes. J Appl Pharm Sci 2013; 3(2): 127-31.
[168]
Angadi KK, Gundampati RK, Jagannadhamb MV, Kandru A. In-vitro biological studies of crude extracts and isolation of novel compound from Nymphaea pubescens leaf. J Free Rad Antioxid Photon 2013; 139: 122-9.
[171]
Grewal AS, Sharma N, Singh S, Arora S. Molecular docking studies of phenolic compounds from Syzygium cumini with multiple targets of type 2 diabetes. J Pharm Technol Res Manag 2018; 6(2): 125-33.
[178]
Bizzarro FT, Corbett WL, Focella A. inventor; Hoffmann-La
Roche, assignee. Glucokinase activators World Intellectual Property
Organization WO 2000058293. 2000.
[179]
Caulkett P, Johnstone C, Mckerrecher D, Pike KG. inventor;
AstraZeneca, assignee. Pyridine carboxylic acid derivatives as glucokinase
modulators World Intellectual Property Organization WO
2005044801. 2005.
[180]
Johnstone C, Mckerrecher D, Pike KG. inventor; AstraZeneca,
assignee. Benzoyl amino pyridyl carboxylic acid derivatives useful
as glucokinase (GLK) activators World Intellectual Property Organization
WO 2005054200. 2005.
[181]
Caulkett P, Johnstone C, Mckerrecher D, Pike KG. inventor;
AstraZeneca, assignee. Benzoyl amino pyridyl carboxylic acid derivatives
useful as glucokinase (GLK) activators World Intellectual
Property Organization WO 2005056530. 2005.
[182]
Johnstone C, Mckerrecher D, Pike KG. inventor; AstraZeneca,
assignee. Benzamide derivatives and their use as glucokinae activating
agents World Intellectual Property Organization WO
2005080359. 2005.
[183]
Johnstone C, Mckerrecher D, Pike KG, Waring MJ. inventor;
AstraZeneca, assignee. Benzamide derivatives that act upon the
glucokinase enzyme World Intellectual Property Organization WO
2006040529. 2006.
[184]
Johnstone C, James R, Mckerrecher D. Inventor; AstraZeneca,
assignee. Compound effecting glucokinase European Patent EP
1661563. 2006.
[185]
Johnstone C, Mckerrecher D, Pike KG. inventor; AstraZeneca,
assignee. Benzoyl amino pyridyl carboxylic acid derivatives as
glucokinase activators European Patent EP 1689741. 2006 Aug;
[186]
Mckerrecher D, Pike KG, Waring M. inventor; AstraZeneca, assignee. Heteroaryl benzamide derivatives for use as GLK activators
in the treatment of diabetes World Intellectual Property Organization
WO 2006125972. 2006 Nov;
[187]
Mckerrecher D, Pike KG, Waring M. inventor; AstraZeneca, assignee. 2-Heterocyclyloxybenzoyl amino heterocyclyl compounds
as modulators of glucokinase for the treatment of type 2 diabetes World Intellectual Property Organization 2007007040. 2007 Jan;
[188]
Mckerrecher D, Pike KG, Waring MJ. inventor; AstraZeneca,
assignee. Heteroarylcarbamoyl-benzene derivatives for the treatment
of diabetes World Intellectual Property Organization WO
2007017649. 2007.
[189]
Murray A, Lau J, Jeppesen L, Vedso P. inventor; TransTech Pharma,
assignee. Benzamide glucokinase activators World Intellectual
Property Organization WO 2007125103. 2007.
[190]
Martin NG, Mckerrecher D, Pike KG, Waring MJ. inventor; Astra-
Zeneca, assignee. Benzoyl amino heterocyclyl compounds as glucokinase
(GLK) activators World Intellectual Property Organization
WO 2008050117. 2008.
[191]
Chen S, Cheng P, Smirk R. inventor; Bristol-Myers Squibb, assignee. 1,3-Dihydroxy substituted phenylamide glucokinase activators World Intellectual Property Organization WO 2008154563. 2008.
[192]
Tian F, Dang Q, Prasad GS. inventor; Metabasis Therapeutics,
assignee. Novel activators of glucokinase World Intellectual Property
Organization WO 2009023718. 2009.
[193]
Burgdorf L, Carniato D, Emde U, Beier N, De Gleitz J, De Charon C. inventor; Merck Patent GmbH, assignee. N-(Pyrazole-3-yl)-
benzamide derivatives as glucokinase activators World Intellectual
Property Organization WO 2009046802. 2009.
[194]
Murray A, Lau J, Jeppesen L. inventor; TransTech, assignee. Benzamide glucokinase activators United States patent US
20100331379. 2010.
[195]
Kharul R. inventor; Cadila Healthcare, assignee. Disubstituted
benzamide derivatives as glucokinase (GK) activators World Intellectual
Property Organization WO 2010150280. 2010.
[196]
Yi W, Han T, Lee K. inventor; Yuhan Corporation, assignee. Novel glucokinase activators and processes for the preparation
thereof World Intellectual Property Organization WO 2011081280. 2011.
[197]
Deshpande A, Kandalkar S, Naik K, Dave B, Bhuniya D, Palle V. inventor; Advinus Therapeutics, assignee. Benzamide compounds
as glucokinase activators and their pharmaceutical application World Intellectual Property Organization WO 2011095997. 2011.
[198]
Park KJ, Lee BM, Lee DH, Choi HH, Hyun KH, Lee CH. inventor;
Yuhan Corporation, assignee. Novel phenylethynyl benzamide
glucokinase activator and method for preparing same World Intellectual
Property Organization WO 2014112798. 2014.
[199]
Park KJ, Lee BM, Lee DH, Choi HH, Hyun KH, Lee CH. inventor;
Yuhan Corporation, assignee. Phenoxybenzamide glucokinase activator
containing novel heteroaryl and method for preparing same World Intellectual Property Organization WO 2014112799. 2014.
[200]
Duan W, Shen X, Chen J. inventor; Chinese Academy of Sciences,
assignee. N-Substituted-3,5-disubstituted benzamide compound
and preparation method and application thereof World Intellectual
Property Organization WO 2016112863. 2016.
[201]
Cheng P, Meng W, Liu M, Wang B, Zhao R. inventor; Bristol-
Myers Squibb, assignee. Glucokinase activators and methods of using
same World Intellectual Property Organization WO
2018017910. 2018.
[202]
Cheng P, Meng W, Liu M, Wang B, Zhao R. inventor; Bristol-
Myers Squibb Company, assignee. Glucokinase activators and
methods of using same United States patent US 20190233449. 2019.
[203]
Mahaney PE. Alkynyl Phenyl Heteroaromatic Glucokinase Activators. World Intellectual Property Organization WO 2001083465. 2001.
[204]
Bizzaro FT, Corbett WL, Grippo JF. inventor; Hoffmann-La
Roche, assignee. Heteroaromatic glucokinase activators United
States patent US 20010039344. 2001.
[205]
Bizzarro FT, Haynes NE, Sarabu R. inventor; Hoffmann-La Roche,
assignee. Para-amine substituted phenylamide glucokinase activators World Intellectual Property Organization WO 2001085707. 2001.
[206]
Corbett WE, Haynes NE, Sarabu R. inventor; Hoffmann-La Roche,
assignee. Substituted phenylacetamides and their use as glucokinase
activators World Intellectual Property Organization WO
2001085706. 2001.
[207]
Kester RF, Sarabu R. inventor; Hoffmann-La Roche, assignee. Alpha-acyl and alpha-heteroatom-substituted benzene acetamide
glucokinase activators World Intellectual Property Organization
WO 2002008209. 2002.
[208]
Corbett WL, Grimsby JS, Haynes NE. inventor; Hoffmann-La
Roche, assignee. Substituted phenylacetamides and their use as
glucokinase activators World Intellectual Property Organization
WO 2003095438. 2003.
[209]
Polisetti D, Kodra J, Lau J. inventor; Novo Nordisk, assignee. Aryl carbonyl derivatives as therapeutic agents World Intellectual
Property Organization WO 2004002481. 2004.
[210]
Corbett WL. inventor; Hoffmann-La Roche, assignee. Indole-3-
carboxamides as glucokinase activators United States patent US
20040067939. 2004.
[211]
Weichert AG, Barrett DG, Heuser S, Riedl R, Tebbe MJ, Zaliani A. inventor; Eli Lilly and Company, assignee. Substituted arylcyclopropylacetamides
as glucokinase activators World Intellectual
Property Organization WO 2004063179. 2004.
[212]
Lau JF, Vedsoe P, Kodra JT. inventor; Novo Nordisk, assignee. N-Heteroaryl indole carboxamides and analogues thereof, for use
as glucokinase activators in the treatment of diabetes World Intellectual
Property Organization WO 2005049019. 2005.
[213]
Fyfe MCT, Shah VK. inventor; Prosidion Ltd., assignee. Substituted
phenylacetamides and their use as glucokinase activators World
Intellectual Property Organization WO 2006016194. 2006.
[214]
Jeppesen L, Kristiansen M. inventor; Novo Nordisk, assignee. Heteroaromatic glucokinase activators World Intellectual Property
Organization WO 2006058923. 2006.
[215]
Bebernitz GR. inventor; Novartis Ag, assignee. 3-Cyclyl-2-(4-
sulfamoyl-phenyl)-N-cyclyl-propionamide derivatives useful in the
treatment of impaired glucose tolerance and diabetes World Intellectual
Property Organization WO 2007041365. 2007.
[216]
Cheruvallath Z, Feng J, Guntupalli P. inventor; Takeda San
Diego, assignee. Glucokinase activators World Intellectual Property
Organization WO 2007104034. 2007.
[217]
Berthel S, Kester R, Murphy D. inventor; Hoffmann-La Roche,
assignee. Pyrazole glucokinase activators United States patent US
US20080021032. 2008.
[218]
Cheruvallath Z, Feng J, Guntupalli P. inventor; Takeda San Diego,
assignee. Piperazine derivatives as glucokinase activators World Intellectual Property Organization WO 2008116107. 2008.
[219]
Bhuniya D, Kapkoti GS, Warrier JS. inventor; Advinus Therapeutics,
assignee. Pyrrole-2-carboxamide derivatives as glucokinase
activators, their process and pharmaceutical application World Intellectual
Property Organization WO 2008149382. 2008.
[220]
Bhuniya D, Sandeep B, Gobind S, Venkata P, De S, Mookhtiar K. inventor; Advinus Therapeutics, assignee. Acetamide derivatives as
glucokinase activators, their process and medicinal applications World Intellectual Property Organization WO 2009047798. 2009.
[221]
Shi Y, Cheng PTW, Wang Y, Ryono DE. inventor; Bristol-Myers
Squibb, assignee. Novel glucokinase activators and methods of using
same World Intellectual Property Organization WO
2009018065. 2009.
[222]
Saal C, Burgdorf ZT, Emde U, Beier N, Gleitz J, Charon C. inventor;
Merck Patent GmbH, assignee. 5-Oxo-2,3,4,5-tetrahydrobenzo[
b]oxepine-4-carboxylic acid amides and 2,3-dihydrobenzo[
b]oxepine-4-carboxylic acid amides for treatment and prevention
of diabetes Typ 1 and 2 World Intellectual Property Organization
WO 2009109270. 2009.
[223]
Berthel SJ, Brinkman JA, Hayden S. inventor; Hoffmann-La
Roche, assignee. Pyrrolidinone glucokinase activators World Intellectual
Property Organization WO 2009127546. 2009.
[224]
Berthel SJ, Haynes NE, Kester RF. inventor; Hoffmann-La
Roche, assignee. Pyridazinone glucokinase activators World Intellectual
Property Organization WO 2009127544. 2009.
[225]
Benbow JW, Pfefferkorn JA. inventor; TransTech, assignee. Substituted
pyrazinone amides United States patent US 20100184777. 2010.
[226]
Ling AL, Pfefferkorn JA. inventor; Pfizer, assignee. Benzofuranyl
derivatives United States patent US 20100234285. 2010.
[227]
Haynes NE, Scott NR, Tilley JW. inventor; Hoffmann-La Roche,
assignee. Pyridone glucokinase activators World Intellectual Property
Organization WO 2011009845. 2011.
[228]
Lau J, Kodra J, Guzei M. inventor; Novo Nordisk, assignee. Amide
derivatives useful as glucokinase activators European Patent
EP 2305648.. 2011.
[229]
Sarabu R. inventor; Hoffmann-La Roche, assignee. 3-Oxo-3,9-
dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators World Intellectual Property Organization WO 2011157682. 2011.
[230]
Bhuniya D, Dave B, Deshpande A. inventor; Advinus Therapeutics,
assignee. Acetamide compounds, their process and pharmaceutical
application World Intellectual Property Organization WO
2012020357. 2012.
[231]
Cheruvallath Z, Gwaltney SL, Jennings AJ. inventor; Takeda
California, assignee. Glucokinase activators United States patent
US 20140045859. 2014.
[232]
Fukuda Y, Asahina Y, Takadoi M, Yamamoto M. inventor; Kyorin
Pharmaceutical, assignee. Cyclopentyl-acrylamide derivative United States patent US 8946440. 2015.
[233]
Tian F, Dang Q, Prasad GS. inventor; Metabasis Therapeutics,
assignee. Novel activators of glucokinase United States patent US
20170096440,. 2017.
[234]
Tian F, Dang Q, Prasad SG. inventor; Metabasis Therapeutics,
assignee. Activators of glucokinase United States patent US
10174062.. 2019.
[235]
Chen S, Corbett WL, Guertin KR. inventor; Hoffmann-La Roche,
assignee. 5-Substituted-pyrazine or pyridine glucokinase activators World Intellectual Property Organization WO 2004052869. 2004.
[236]
Aicher TD, Lee WM, Hinklin RJ, Chicarelli MJ, Boyd SA, Condroski KR. inventor; Array Biopharma, assignee. Glucokinase
activators World Intellectual Property Organization WO
2007053345. 2007.
[237]
Aicher TD, Boyd SA, Chicarelli MJ. inventor; Array Biopharma,
assignee. Pyridin-2-amine derivatives and their use as glucokinase
activators Canadian Patent CA 2637172.. 2007.
[238]
Aicher TD, Boyd SA, Chicarelli MJ, Condroski KR, Hinklin RJ, Singh A. inventor; Array Biopharma, assignee. 2-Aminopyridine
analogs as glucokinase activators World Intellectual Property Organization
WO 2007117381. 2007.
[239]
Aicher TD, Boyd SA, Chicarelli MJ. inventor; Array Biopharma,
assignee. 2-Aminopyridine derivatives as glucokinase activators World Intellectual Property Organization WO 2008091770. 2008.
[240]
Aicher TD, Boyd SA, Chicarelli MJ. inventor; Array Biopharma,
assignee. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as
glucokinase activators for the treatment of diabetes mellitus World
Intellectual Property Organization WO 2009042435. 2009.
[241]
Burgdorf LT, Beier N, Gleitz J, Charon C, Cravo D. inventor;
Merck Patent GmbH, assignee. Pyridine derivatives useful as glucokinase
activators World Intellectual Property Organization WO
2009046784. 2009.
[242]
Meng W, Cheng PTW. inventor; Bristol-Myers Squibb, assignee. Novel glucokinase activators and methods of using same United
States patent US 20130029939.. 2013.
[243]
Aicher TD, Boyd SA, Chicarelli MJ, Condroski KR, Hinklin RJ, Singh A. inventor; Array Biopharma, assignee. 2-Aminopyridine
analog as glucokinase activator Japan Patent JP 2013245220. 2013.
[244]
Goodnow R Jr, Le K. inventor; Hoffmann-La Roche, assignee. Hydantoin-containing glucokinase activators World Intellectual
Property Organization WO 2001083478. 2001.
[245]
Feng J, Gwaltney SL, Hosfield DJ. inventor; Takeda San Diego,
assignee. Glucokinase activators World Intellectual Property Organization
WO 2007075847. 2007.
[246]
Cao SX, Feng J, Gwaltney SL. inventor; Takeda San Diego, assignee. Indazole and isoindole derivatives as glucokinase activating
agents World Intellectual Property Organization WO 2007143434. 2007.
[247]
Cho M, Kim H, Kim K, Kim S, Park H, Yoon S. inventor; Lg Life
Sciences, assignee. Glucokinase activators and pharmaceutical
compositions containing the same as an active ingredient World
Intellectual Property Organization WO 2009082152. 2009.
[248]
Corbett JW, Guzman-Perez A, Pfefferkorn JA, Tu MM. inventor;
Pfizer, assignee. Substituted indazole amides and their use as glucokinase
activators World Intellectual Property Organization WO
2010103438. 2010.
[249]
Berthel SJ, Chen L, Corbett WL. inventor; Hoffmann-La Roche,
assignee. Azaindole glucokinase activators World Intellectual
Property Organization WO 2011073117. 2011.
[250]
Berthel SJ, Kester RF, Orzechowski L. inventor; Hoffmann-La
Roche, assignee. Isoindolinone derivatives World Intellectual
Property Organization WO 2012150202. 2012.
[251]
Corbett WL, Grimbsy JS, Haynes NE, Kester RF, Mahaney PE, Sarabu R. inventor; Hoffmann-La Roche, assignee. Fused heteroaromatic
glucokinase activators World Intellectual Property Organization
WO 2002046173. 2002.
[252]
Hashimoto H, Mizutani K, Yoshida A. inventor; Japan Tobacco
Inc., assignee. Fused ring compounds and use thereof United
States patent US 20030050320,. 2003.
[253]
Caulkett P, Mckerrecher D, Newcombe N, Pike KG, Waring M. inventor; AstraZeneca, assignee. 2-Phenyl substituted imidazol
[4,5b] pyridine/ pyrazine and purine derivatives as glucokinase
modulators World Intellectual Property Organization WO
2006125958. 2006.
[254]
Caulkett P, Mckerrecher D, Newcombe N, Pike KG, Robb G, Waring M. nventor; AstraZeneca, assignee. Heterobicyclic compounds
as glucokinase activators World Intellectual Property Organization
WO 2007031739. 2007.
[255]
Dave S, Deshpande A, Kurhade S, Cobalt B, Bhuniya D, Palle V. inventor; Advinus Therapeutics, assignee. Fused nitrogen heterocyclic
compounds, process of preparation and uses thereof World Intellectual
Property Organization WO 2011080755. 2011.
[256]
Andreevich RN, Sergeevna DN, Akhmetovich IR. assignee. 7-(4-
Methoxyphenyl)-5-phenyl-4,5-dihydro-[1,2,4]triazolo[1,5-
a]pyrimidine as activator of glucokinase and inhibitor of dipeptidyl
peptidase of type 4 and method of its production Russian Patent
RU 0002642432.. 2018.
[257]
Murray A, Lau J, Jeppesen L. inventor; Novo Nordisk, assignee. Heteroaryl-ureas and their use as glucokinase activators World Intellectual
Property Organization WO 2005066145. 2005.
[258]
Lau J, Murray A, Vedso P, Kristiansen M, Jeppesen L. inventor;
Novo Nordisk, assignee. Urea glucokinase activators World Intellectual
Property Organization WO 2007006814. 2007.
[259]
Murray A, Lau J, Vedsoe P, Jeppesen L, Kristiansen M. inventor;
Novo Nordisk, assignee. Dicycloalkylcarbamoyl ureas as glucokinase
activators World Intellectual Property Organization WO
2007006761. 2007.
[260]
Murray A, Lau J, Vedso P, Kristiansen M, Jeppesen L. inventor;
Novo Nordisk, assignee. Dicycloalkyl urea glucokinase activators European Patent EP 1904466.. 2008.
[261]
Houze JB, Dransfield P, Pattaropong V. inventor; Array Biopharma,
assignee. Urea compounds as GKA activators World Intellectual
Property Organization WO 2013086397. 2013.
[262]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. N-Adamantane amide type compound containing p-nitrophenyl,
preparation method and application thereof Chinese Patent CN
104628616.. 2015.
[263]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. N-Phenyl adamantane amide type glucokinase activator as well as
preparation method and application thereof Chinese Patent CN
104610112.. 2015.
[264]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. A class of phenyl substituted by alkoxy N-adamantane amide compounds
and use thereof Chinese Patent CN 104610114.. 2015.
[265]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. N-Phenyl adamantane amide type compound containing nitrobenzene
and application of N-phenyl adamantane amide type compound Chinese Patent CN 104610115.. 2015.
[266]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Glucokinase activator containing glucosamide structure, preparation
method and application of glucokinase activator to treatment
of type II diabetes mellitus Chinese Patent CN 104672218.. 2015.
[267]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Glucokinase activator containing glucosamide and pyridine structure
and application of glucokinase activator Chinese Patent CN
104610241.. 2015.
[268]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Compound containing glucosamide pyridine and alkoxypyrazine
structure and application of compound Chinese Patent CN
104610242.. 2015.
[269]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Glucokinase activator containing glucosamide and pyridine structure
and application thereof Chinese Patent CN 104610243.. 2015.
[270]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Compound containing glucosamide pyridine and alkoxy pyrazinyl
structure and application thereof Chinese Patent CN 104592214,. 2015.
[271]
Bebernitz GR. inventor; Novartis Ag, assignee. Substituted (thiazol-
2-yl)-amide or sulfonamide as glycokinase activators useful in
the treatment of type 2 diabetes World Intellectual Property Organization
WO 2004050645. 2004.
[272]
Bebernitz GR, Gupta RC, Jagtap VV, Mandhare AB, Tuli D. inventor;
Novartis Ag, assignee. Sulfonamide-thiazolpyridine derivatives
as glucokinase activators useful the treatment of type 2 diabetes World Intellectual Property Organization WO 2005095418. 2005.
[273]
Bebernitz GR, Kerman L. inventor; Novartis Ag, assignee. Sulfonamide
derivatives as glycokinase activators useful in the treatment
of type 2 diabetes World Intellectual Property Organization WO
2007041366. 2007.
[274]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Glucokinase activator containing quinoline structure as well as
preparation method and application thereof Chinese Patent CN
104672133.. 2015.
[275]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Glucokinase Activator containing nitroquinoline structure and application
of glucokinase activator Chinese Patent CN 104628616.. 2015.
[276]
Ziyang C. inventor; Foshan Saives Medical Technology, assignee. Glucokinase activator containing quinoline and cyano benzene
structure, and application thereof Chinese Patent CN 104592113.. 2015.
[277]
Burgdorf LT, Emde U, Gleitz J, Beier N, Charon C. inventor;
Merck Patent GmbH, assignee. Glucokinase activators World Intellectual
Property Organization WO 2009106203. 2009.
[278]
Burgdorf L, Emde U, Graits J, Bahia N, Sharon C. inventor; Merck
Patent GmbH, assignee. Glucokinase activator Japan Patent JP
2014208665.. 2014.
[279]
Sidduri A. inventor; Hoffmann-La Roche, assignee. Tetrazolylphenyl
acetamide glucokinase activators World Intellectual Property
Organization WO 2002014312. 2002.
[280]
Guertin KR. inventor; Hoffmann-La Roche, assignee. Isoindolin-1-
one glucokinase activators World Intellectual Property Organization
WO 2002048106. 2002.
[281]
Caulkett P, Currie G, Hargreaves R, Hayter B, James R. inventor;
AstraZeneca, assignee. Vinyl phenyl derivatives as GLK activators World Intellectual Property Organization WO 2003000262. 2003.
[282]
Cao SX, Feng J, Gwaltney SL. inventor; Takeda San Diego, assignee. Glucokinase activators World Intellectual Property Organization
WO 2007061923. 2007.
[283]
Ryono DE, Cheng P, Bolton S. inventor; Bristol-Myers Squibb,
assignee. Phosphonate and phosphinate compounds as glucokinase
activators World Intellectual Property Organization WO
2008005964. 2008.
[284]
Berthel S, Kester R, Murphy D. nventor; Hoffmann-La Roche,
assignee. Oxime glucokinase activators United States patent US
20080146625.. 2009.
[285]
Mookhtiar KA, Bhuniya D, Dave B. inventor; Advinus Therapeutics,
assignee. 2,2,2-Tri-substituted acetamide derivatives as glucokinase
activators, their process and pharmaceutical application World Intellectual Property Organization WO 2008104994. 2008.
[286]
Badiger S, Fosgerau K, Wrong N. inventor; Rheoscience, assignee. Azine compounds as glucokinase activators World Intellectual
Property Organization WO 2009083553. 2009.
[287]
Bender S, Burgdorf LT, Emde U, Beier N, Gleitz J, Charon C. inventor; Merck Patent GmbH, assignee. Beta-amino acid derivatives
for treatment of diabetes World Intellectual Property Organization
WO 2009092432. 2009.
[288]
Benbow JW, Lou J, Pfefferkorn JA, Tu MM. inventor; Pfizer,
assignee. Fluorinated heteroaryls World Intellectual Property Organization
WO 2010013161. 2010.
[289]
Corbett WL, Sarabu R, Sidduri A. inventor; Hoffmann-La Roche,
assignee. Trans olefinic glucokinase activators World Intellectual
Property Organization WO 2001044216. 2001.
[290]
Well MA, Agejas-Chicharro FJ. inventor; Eli Lilly and Company,
assignee. Arylcyclopropylacetamide derivatives useful as glucokinase
activators World Intellectual Property Organization WO
2010080333. 2010.
[291]
Aspnes GE, Didiuk MT, Guzman-Perez A, Maguire RJ. inventor;
Pfizer, assignee. 2-(3,5-Disubstitutedphenyl)pyrimidin-4(3H)-one
derivatives World Intellectual Property Organization WO
2011158149. 2011.
[292]
Tian F, Dang Q, Prasad GS. inventor; Metabasis Therapeutics,
assignee. Activators of glucokinase United States patent US
20150119365.. 2015.
[293]
Guolei Z, Yuan H, Yunping Z. inventor; Beijing Venturepharm
Biotech Azaindole, assignee. Compound used as glucokinase activator Chinese Patent CN 106518866.. 2017.